Pharmacokinetics and tolerability of meloxicam after i.m. administration

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 135-139

  Narjes, H ^a   Turck D ^a   Busch, U ^a   Heinzel, G ^a   Nehmiz, G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

i.m., i.v.; Meloxicam; Pharmacokinetics; Tolerability

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0030024644     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00171.x     Document Type: Article

References (12)

1. Wiseman RL, Kilgour M. Intramuscular piroxicam, a new drug dosage form, in the treatment of acute musculoskeletal disorders. J Int Med Res 1985; 13: 255-262.
2. Nuutinen LS, Laitinen JO, Salomaki TE. A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain. Drug Safety 1993; 9: 380-393.
3. Dougados M, Listrat V, Duchesne L, Amor B. Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double-blind study versus placebo in rheumatoid arthritis. Rev Rhum Mal Osteoartic 1992; 59: 769-773.
4. Eandi M, Buraglio M, Casilli D, Grazia De Lucia M, Ruffilli MP. Injectable piroxicam in acute musculoskeletal disorder: Results of a multicenter study. Curr Ther Res 1989; 45: 381-397.
5. Vaccarino V, Sistori CR, Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr Ther Res 1989; 45: 1-13
6. Engelhardt G, Homma D, Schlegel K, Schnitzler Chr, Utzmann R. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal antiinflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; (in press).
7. Engelhardt G. Meloxicam. Potent inhibitor of adjuvant-induced arthritis in the rat. Scand J. Rheumatol 1994; 98 (Suppl.): 110, Abstract.
8. Lemmel EM, Bolten W, Burgos-Vargas R, et al. A double-blind placebo controlled study of 7.5 mg and 15 mg meloxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994; 98 (Suppl.): 111, Abstract.
9. Linden B, Distel M, Bluhmki E. Double-blind randomized comparison of meloxicam and piroxicam in patients with osteoarthritis (OA) of the hip. Scand J Rheumatol 1994; 98 (Suppl.): 182.
10. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Lea & Febiger, 4th ed., Philadelphia, London, 1991.
11. Türck D, Busch U, Heinzel G, Narjes, H. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995; 9: 270-276.
12. Michos N, Zulliger HW, Fenzl E. Pharmacokinetics and tolerability of suprofen. Experience with intramuscular application in healthy volunteers. Arzneim-Forsch 1985; 35: 738-745.